Pentixapharm Raises EUR 20.4 Million Through Oversubscribed Offering

Pentixapharm Holding AG has successfully completed its rights offering and subsequent private placement. The initiatives resulted in significant oversubscription, generating gross proceeds of approximately EUR 20.4 million. Announced on July 1, 2026, the capital increase led to the placement of 11,020,221 new shares with both existing shareholders and new investors.

The company's share capital will rise to EUR 35.8 million following the registration of the capital increase. After deducting transaction costs, net proceeds are estimated at EUR 19.65 million. Pentixapharm plans to allocate these funds to key steps in the PANDA Phase 3 trial, corporate expansion into the US, and enhancing manufacturing and supply infrastructure. Additionally, the proceeds will support the development of CXCR4-based theranostic platforms, such as PentixaTher, in hematology-oncology, and bolster the company's equity base and working capital.